Home / Resource Library / A phase 2, open‑label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemiaA phase 2, open‑label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia